MK-677 (Ibutamoren): What People Report When Switching To or From This Drug

What MK-677 Actually Does to GH and IGF-1

MK-677 mimics ghrelin at the growth-hormone secretagogue receptor (GHS-R1a), triggering pulsatile GH release from the anterior pituitary without suppressing the hypothalamic-pituitary axis the way exogenous GH does. In the longest published trial, Murphy et al. followed 65 healthy older adults for two years on 25 mg/day and found that ibutamoren raised mean IGF-1 levels by approximately 40% at 6 months and sustained that elevation through month 24, bringing IGF-1 into the range typical of younger adults 1. GH pulsatility remained intact. Fat-free mass increased by roughly 1.6 kg over the first year without a structured exercise program.

This pharmacology matters for switching decisions. Because MK-677 works through the body's own GH axis rather than replacing it, the transition profile differs from injectable recombinant GH (rhGH). The pituitary is still active, meaning there is no axis suppression to recover from when stopping. But the magnitude of IGF-1 rise is generally lower than what supraphysiologic rhGH doses achieve 2.

Switching From Injectable GH to MK-677: What Users Report

The most commonly discussed transition on Reddit's r/PEDs, r/Peptides, and r/Bodybuilding forums involves moving from daily subcutaneous GH injections (typically 2-4 IU rhGH) to oral MK-677. Selection bias is significant here: the people posting are generally younger males in bodybuilding or anti-aging contexts, not representative of the general population.

Reported positives of the switch include elimination of daily injections, lower cost (MK-677 is available through grey-market research chemical vendors, though product quality is unverified), and the convenience of a single oral dose. One frequently cited Reddit user summarized the transition: "Went from 3 IU pharma GH to 25 mg MK. Sleep quality stayed the same, maybe slightly worse. The appetite increase was way more aggressive than anything GH ever did to me."

Reported negatives cluster around three themes. First, water retention. Multiple users describe gaining 4-8 lbs of water weight within the first 7-10 days on MK-677 that they did not experience on injectable GH at moderate doses. This aligns with known aldosterone-stimulating properties of ghrelin-receptor agonists 3. Second, appetite stimulation. MK-677 acts on the same receptor as ghrelin, the primary hunger hormone. Users cutting calories for fat loss frequently describe this effect as deal-breaking. Third, the IGF-1 ceiling. Forum consensus suggests MK-677 at 25 mg/day produces IGF-1 levels roughly equivalent to 1.5-2 IU of rhGH, meaning users previously on higher GH doses (4+ IU) often feel the switch is a step down in anabolic effect.

No controlled trial has directly compared switching outcomes between these agents.

Switching From MK-677 to Injectable GH or Peptides

Users who transition in the opposite direction, from MK-677 to rhGH or GH-releasing peptides like CJC-1295/ipamorelin, tend to report the following pattern. Appetite normalizes within 3-5 days of stopping MK-677. Water retention drops over roughly 7-10 days. IGF-1 levels, when tracked via bloodwork, appear to return to pre-MK-677 baseline within 2-4 weeks based on user-posted labs, though no formal discontinuation pharmacokinetic study has been published.

The Murphy et al. trial offers partial guidance here. After two years of continuous 25 mg dosing, the investigators noted that GH and IGF-1 returned to baseline levels after drug discontinuation, and fat-free mass gains were not maintained in the year following cessation 1. This suggests that MK-677's body composition effects depend on continued use. It is not a "prime and stop" agent.

Users switching to CJC-1295/ipamorelin combos frequently note that the peptide stack offers more targeted GH pulses with less appetite stimulation, though it reintroduces the inconvenience of subcutaneous injections (typically 2-3 times daily for ipamorelin). A Drugs.com review of ibutamoren stated: "Switched to ipam/CJC after 6 months on MK. Better sleep on the peptides, way less bloating, but I missed just swallowing a pill."

Blood Glucose and Insulin: A Switching Consideration Often Overlooked

MK-677 has a documented effect on glucose metabolism that complicates long-term use and switching decisions. In the Murphy et al. two-year trial, fasting blood glucose increased by an average of 0.3 mmol/L (approximately 5 mg/dL), and some subjects developed impaired fasting glucose 1. A separate study by Nass et al. (2008) in healthy older adults confirmed that ibutamoren 25 mg/day for one year increased fasting glucose and HbA1c modestly but significantly, with an average HbA1c rise of 0.12% 4.

For individuals with pre-existing insulin resistance, type 2 diabetes risk factors, or those using MK-677 alongside other GH-axis stimulants, this glucose effect is clinically meaningful. Forum users with glucometers report fasting glucose increases of 5-15 mg/dL on MK-677. Several accounts describe switching away from MK-677 specifically because of rising fasting glucose, with levels normalizing within 2-3 weeks post-discontinuation.

The Endocrine Society's 2019 clinical practice guideline on GH use in adults notes that GH-related insulin resistance is a known class effect and recommends glucose monitoring during any GH-elevating therapy 5. This recommendation, while written for rhGH, applies logically to GH secretagogues.

What Switching Timelines Look Like in Practice

There are no published switching protocols for MK-677 because it is not an approved medication. The timelines below are derived from user reports and pharmacologic principles. They are not medical recommendations.

Starting MK-677: IGF-1 typically begins rising within 2-4 days. Steady-state IGF-1 elevation is usually reached by day 10-14. Appetite increase and water retention are most noticeable in the first 1-2 weeks and partially attenuate by week 4 in some users, though not all.

Stopping MK-677: Because MK-677 does not suppress the pituitary axis, there is no "post-cycle" recovery needed in the way anabolic steroids require PCT. IGF-1 returns to baseline within 2-4 weeks. The speed of this normalization is consistent with MK-677's mechanism: once the ghrelin-receptor agonism stops, GH secretion reverts to its natural pattern.

Overlapping with rhGH: Some users report running MK-677 and low-dose rhGH simultaneously for a "bridging" period when switching between the two. No clinical data support this practice. From a pharmacologic standpoint, exogenous GH will suppress endogenous GH pulsatility via negative feedback, which would partially negate MK-677's pulsatile GH release mechanism. The combination may raise IGF-1 higher than either agent alone, but it also compounds insulin resistance risk.

The Appetite Problem: Why Many Users Switch Away

Appetite stimulation deserves its own section because it is, by a wide margin, the most commonly cited reason users discontinue MK-677. Ghrelin is the body's primary orexigenic hormone. MK-677 is a potent ghrelin-receptor agonist. The hunger effect is not a side effect in the traditional sense; it is a direct pharmacologic consequence of the drug's mechanism 6.

Reddit threads on r/PEDs and r/Peptides are filled with accounts of users who started MK-677 for its GH-boosting properties but stopped within 1-3 months because the appetite surge undermined their dietary goals. This is especially common among users trying to lose fat while preserving muscle. "I wanted the GH benefits for recovery but couldn't stop eating," is a representative sentiment. Dose reduction to 10-12.5 mg partially mitigates the hunger for some users, though it also reduces the IGF-1 response proportionally.

Some users report that taking MK-677 at bedtime (rather than morning) reduces the subjective appetite effect, presumably because the peak ghrelin-receptor activation occurs during sleep. This approach has no published validation, but it is widely discussed in forum communities. A study by Copinschi et al. showed that MK-677 given at bedtime enhanced sleep quality and increased the duration of REM and stage IV sleep in young men 7, lending some pharmacologic plausibility to the timing strategy.

Forum Consensus vs. Clinical Reality: Critical Caveats

Self-reported experiences with MK-677 carry substantial limitations that users considering a switch should understand. Selection bias is pervasive. People who had dramatic positive or negative experiences are far more likely to post than those with unremarkable outcomes. There is no way to verify the actual product consumed. Grey-market MK-677 capsules and liquids are not pharmaceutical grade; they vary in purity, concentration, and may contain contaminants or entirely different compounds. Bloodwork posted on forums, while useful, is rarely accompanied by pre-drug baselines, controlled timing, or verification of the testing methodology.

MK-677 has never completed a Phase III trial for any indication. The existing published studies are small (N=32 to N=65), short by chronic-use standards (up to two years), and conducted in older adults or specific clinical populations such as hip-fracture patients 8 and obese males 9. Extrapolating these data to young, healthy bodybuilders using the drug for performance purposes requires caution.

The compound remains unapproved by the FDA. It is listed by the World Anti-Doping Agency (WADA) as a prohibited substance both in-competition and out-of-competition under section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) 10. Athletes subject to drug testing should be aware that MK-677 metabolites are detectable in urine.

How MK-677 Compares to Other GH-Boosting Options for Switching Purposes

For users weighing MK-677 against alternatives, the practical differences break down along several axes. Injectable rhGH offers the most predictable, dose-dependent IGF-1 elevation but requires daily subcutaneous injections, cold-chain storage, and is significantly more expensive (often $300-800/month for pharmaceutical-grade product). GHRP/GHRH peptide combinations (e.g., ipamorelin + CJC-1295 DAC) work through the same axis as MK-677 but require injection and produce less appetite stimulation. Sermorelin, an FDA-approved GHRH analog, stimulates GH release but has a shorter half-life and produces a more modest IGF-1 rise than MK-677 at standard clinical doses 11.

The choice between these agents depends on individual priorities: convenience (favors MK-677), appetite neutrality (favors ipamorelin or rhGH), magnitude of IGF-1 response (favors rhGH), and regulatory status (favors sermorelin or rhGH with a prescription).

Any transition between GH-axis agents should include baseline and follow-up IGF-1 and fasting glucose testing to monitor response. A minimum 4-week washout between agents allows for reliable comparison of pre- and post-switch IGF-1 levels.